It has been demonstrated that the presence of PD-L1 determines the response to anti-PD-1/PD-L1 therapy (Sunshine et al., 2017), regorafenib can promotes antitumor immunity via inhibiting PD-L1 expression in melanoma (Wu et al., 2019). This evidence concerns the gene PDCD1 and melanoma.